Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas

Leukemia and Lymphoma

Volumn 40, Issue 5-6, 2001, Pages 461-470

  Erlanson, M ^a   Landberg, G ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Cyclin E protein; Malignant lymphoma; P27; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; PROTEIN P27;

CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DAMAGE; CELL PROLIFERATION; CHROMOSOME ABERRATION; CLINICAL FEATURE; CONTROLLED STUDY; DEREGULATION; DISEASE ASSOCIATION; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC DAMAGE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INHIBITION; PHASE TRANSITION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW;

EID: 0035048540     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097645     Document Type: Review

References (56)

1. Cancer cell cycles
2. Cell cycle checkpoints: Preventing an identity crisis
3. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function
4. Inhibition of cyclin-dependent kinases by p21
5. Aberrations of the G1- and G1/S-regulating genes in human cancer
6. Alterations of the cyclin D1/p16-pRb pathway in mantle cell lymphoma
7. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group
8. Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia
9. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies
10. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression
11. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies
12. Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas
13. P19(ARF) stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2
14. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
15. Expression of p16INK4A and p14ARF in hematological malignancies
16. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies
17. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition
18. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein
19. Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression
20. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E
21. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
22. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status
23. Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer
24. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas
25. Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage
26. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue
27. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications
28. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation
29. Cioning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
30. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation
31. P27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma
32. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms
33. Role of c-myc and p27 in anti-IgM induced B-lymphoma apoptosis
34. Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27
35. Role of cyclin A and p27 in anti-IgM induced G1 growth arrest of murine B-cell lymphomas
36. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: P27KIP1 expression is inversely proportional to the proliferative index
37. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer
38. Prognostic significance of p27(Kip1) expression in colorectal cancer: A clinico-pathological characterization
39. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: Independent prognostic value of p27Kip1
40. P27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome
41. Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation
42. P27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
43. P27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27
44. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma
45. Expression of p27kip1 in prostatic adenocarcinoma
46. Low p27 expression predicts poor disease-free survival in patients with prostate cancer
47. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
48. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
49. Expression of cyclin dependent kinase inhibitor p21WAF1 alone and in combination with p27KIP1 shows prognostic value in gastric carcinoma
50. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas
51. Overexpression of cyclin E in acute myelogenous leukemia
52. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias
53. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma
54. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia
55. Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma
56. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents